Company: DMAAR
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001213900-25-026240
Chunk: 361

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 3
Chunk 361
---
2024. The Company was incorporated for the purpose of
effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination
with one or more businesses (the “Business Combination”). The Company has not selected any Business Combination target
and it has not, nor has anyone on its behalf, initiated any substantive discussions, directly or indirectly, with any Business Combination
target with respect to an initial Business Combination.

Although the Company may acquire a business in
any industry, it intends to focus on companies in the pharmaceutical industry. The Company is an early stage and emerging growth company
and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies.

As of December 31, 2024, the Company had not commenced
any operations. All activity for the period from May 23, 2024 (inception) through December 31, 2024 relates to the Company’s
formation and the initial public offering (“Initial Public Offering”), which is described below. The Company will not generate
any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate non-operating
income in the form of interest income from the proceeds derived from the Initial Public Offering.

The registration statement for the Company’s
Initial Public Offering was declared effective on January 7, 2025 and the post-effective amendment to the registration statement was declared
effective on January 27, 2025. On January 29, 2025, the Company consummated the Initial Public Offering of 20,000,000 units (the “Units”
and, with respect to the ordinary shares included in the Units being offered, the “Public Shares”) at $10.00 per Unit, generating
proceeds of $200,000,000, which is described in Note 3. On February 18, 2025, the underwriters exercised their over-allotment option to
purchase an additional 3,000,000 Units at a purchase price of $10.00 per Unit, generating additional gross proceeds of $30,000,000, which
is described in Note 3.

Simultaneously with the closing of the Initial
Public Offering, the Company consummated the sale of 400,000 units (the “Private Placement Units”) at a price of $10.00 per
Private Placement Unit in a private placement to Drugs Made In America Acquisition LLC (